| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 74566 |
DOTA-Gd-Au PENPs mPEG修饰钆螯合剂包裹金纳米粒 |
91 |
h |
2024-12-18 |
| 74567 |
Fmoc-Gly3-Val-Cit-PAB-PNP烷基链定制 |
107 |
zyl |
2024-12-18 |
| 74568 |
cas:1268488-70-5，Bis-PEG9-acid，4,7,10,13,16,19,22,25,28-九氧杂三十一烷-1,31-二酸 |
72 |
kx |
2024-12-18 |
| 74569 |
DOTA-SSTa DOTA修饰SSTa抑制剂 |
114 |
h |
2024-12-18 |
| 74570 |
CAS号为1350456-56-2的Fmoc-Val-Cit-PAB-MMAE |
71 |
WYQ |
2024-12-18 |
| 74571 |
CAS号为2353409-69-3的Mal-PEG8-Val-Cit-PAB-MMAE |
96 |
WYQ |
2024-12-18 |
| 74572 |
cy5.5-QS cy5.5荧光标记VEGF125-136小肽QS |
78 |
h |
2024-12-18 |
| 74573 |
THP-SS-PEG1-Boc CAS:1807503-88-3 |
78 |
zyl |
2024-12-18 |
| 74574 |
cas:132178-37-1，Propargyl-C1-NHS ester，2, 5-二氧代吡咯烷-1-基 戊-4-炔酸酯 |
64 |
kx |
2024-12-18 |
| 74575 |
CAS号为646502-53-6的MC-Val-Cit-PAB-MMAE |
88 |
WYQ |
2024-12-18 |
| 74576 |
DOTA-ECL1i 7-氨基酸CCR2结合肽[外环1变型(ECL1i)]偶联DOTA大环配体 |
85 |
h |
2024-12-18 |
| 74577 |
MC-EVCit-PAB-MMAE（CAS号：2873452-49-2） |
72 |
WYQ |
2024-12-18 |
| 74578 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
69 |
h |
2024-12-18 |
| 74579 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
71 |
h |
2024-12-18 |
| 74580 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
74 |
h |
2024-12-18 |
| 74581 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
66 |
h |
2024-12-18 |
| 74582 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
70 |
h |
2024-12-18 |
| 74583 |
Ald-CH2-PEG2-CH2CO2 tBu ester，cas:2230956-95-1 |
76 |
zyl |
2024-12-18 |
| 74584 |
cas:796073-55-7，4-Methyl-4-(methyldisulfanyl)pentanoic acid，4-甲基-4-(甲基二硫烷基)戊酸 |
62 |
kx |
2024-12-18 |
| 74585 |
Ad-PG-FA 线性聚缩水甘油修饰叶酸靶向分子 |
82 |
h |
2024-12-18 |
| 74586 |
三嵌段共聚物PCL-PEEGE-PCL |
161 |
h |
2024-12-18 |
| 74587 |
炔基功能化的聚乙二醇(alkynyl-PEG) |
59 |
h |
2024-12-18 |
| 74588 |
cas:784105-33-5，Amino-PEG3-C2-acid，3-[2-[2-(2-氨基乙氧基)乙氧基]乙氧基]丙酸 |
80 |
kx |
2024-12-18 |
| 74589 |
Phthalamidoxy-PEG2-CH2-ald，cas:1415246-44-4 |
70 |
zyl |
2024-12-18 |
| 74590 |
甘草次酸偶联Gd-DOTA(GGD) |
59 |
h |
2024-12-18 |
| 74591 |
Fmoc-NH-PEG6-CH2COOH，cas:437655-96-4 |
59 |
zyl |
2024-12-18 |
| 74592 |
cas:557756-85-1，Fmoc-NH-PEG4-CH2CH2COOH，5,8,11,14-四氧杂-2-氮杂十七烷二酸1-(9H-芴-9-基甲基)酯 |
83 |
kx |
2024-12-18 |
| 74593 |
DOTA-3-酪氨酰基-奥曲肽 DOTA-TATE |
74 |
h |
2024-12-18 |
| 74594 |
DBCO-DOTA-Eu 叠氮功能化修饰OTA-Eu |
158 |
h |
2024-12-18 |
| 74595 |
HO-PEG10-CH2COOtBu |
75 |
zyl |
2024-12-18 |
| 74596 |
cas:1026987-94-9，DUPA(OtBu)-OH |
68 |
kx |
2024-12-18 |
| 74597 |
NOTA/DFO-MAL-Cys-MZHER2 亲和体Cys-MZHER2偶联螯合剂NOTA/DFO-MAL |
80 |
h |
2024-12-18 |
| 74598 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-Cit-PAB-MMAE) |
80 |
WYQ |
2024-12-18 |
| 74599 |
Propargyl-PEG2-CH2CO2-NHS ester，cas:2244145-13-7 |
78 |
zyl |
2024-12-18 |
| 74600 |
NHS ester-PEG4-Val-Cit-PAB-MMAE，（二苯并环辛炔N-羟基琥珀酰亚胺酯） |
165 |
WYQ |
2024-12-18 |
| 74601 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-1-柰丙氨酸-奥曲肽 DOTA-NOC |
72 |
h |
2024-12-18 |
| 74602 |
CAS号为1350456-56-2的Fmoc-Val-Cit-PAB-MMAE |
66 |
WYQ |
2024-12-18 |
| 74603 |
Azido-PEG3-CH2CO2Me，cas:1253389-31-9 |
65 |
zyl |
2024-12-18 |
| 74604 |
cas:60444-78-2，Ald-Ph-NHS ester，4-甲酰苯甲酸N-琥珀酰亚胺酯 |
123 |
kx |
2024-12-18 |
| 74605 |
荧光染料sulfo-Cy5.5-NHS酯 |
104 |
h |
2024-12-18 |
| 74606 |
DOTA-NVVRQ DOTA-TMTP1 双功能螯合剂DOTA偶联多肽TMTP1(NVVRQ) |
89 |
h |
2024-12-18 |
| 74607 |
CAS号为2353409-69-3的Mal-PEG8-Val-Cit-PAB-MMAE |
103 |
WYQ |
2024-12-18 |
| 74608 |
聚DOTA新型树枝状分子(PDOTA) |
95 |
h |
2024-12-18 |
| 74609 |
Anti-EGFR (cetuximab)-EDC/NHS-methotrexate |
144 |
kx |
2024-12-18 |
| 74610 |
CAS号为646502-53-6的MC-Val-Cit-PAB-MMAE |
131 |
WYQ |
2024-12-18 |
齐岳微信公众号
官方微信
库存查询